Flotufolastat

Flotufolastat is a prostate-specific membrane antigen (PSMA) modulator. Flotufolastat is also a radiodiagnostic agent used in prostate cancer imaging. Flotufolastat can be used in research on prostate cancer and other cancers[1][2].

Product Specifications

CAS Number

[2305060-41-5]

UNSPSC

12352211

Target

PSMA

Related Pathways

Immunology/Inflammation

Field of Research

Cancer

Smiles

CC(C)(C)[Si](F)(C1=CC=C(C=C1)C(NC[C@@H](NC(CC[C@H](N2CCN(CCN(CCN(CC2)CC(O)=O)CC(O)=O)CC(O)=O)C(O)=O)=O)C(N[C@@H](C(O)=O)CCCCNC(CCC(NCCC[C@H](C(O)=O)NC(CC[C@@H](C(O)=O)NC(N[C@H](C(O)=O)CCC(O)=O)=O)=O)=O)=O)=O)=O)C(C)(C)C

Molecular Formula

C63H99FN12O25Si

Molecular Weight

1471.61

References & Citations

[1]Heo YA. Flotufolastat F 18: Diagnostic First Approval. Mol Diagn Ther. 2023 Sep;27 (5) :631-636. |[2]Vogel MME, et al. Biochemical failure-free survival of 18F-rhPSMA-7 and 18F-flotufolastat PET-guided salvage radiotherapy for patients with recurrent prostate cancer. Sci Rep. 2025 Jan 17;15 (1) :2234.